Company Analysis Denali Therapeutics Inc.
1. Summary
Advantages
- Price (13.42 $) is less than fair price (17.99 $)
- Current debt level 3.54% is below 100% and has decreased over 5 years from 12.45%.
- The company's current efficiency (ROE=-37.4%) is higher than the sector average (ROE=-83.36%)
Disadvantages
- Dividends (0%) are below the sector average (1.26%).
- The stock's return over the last year (-30.14%) is lower than the sector average (-21.87%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Denali Therapeutics Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.5% | -37% | 0.8% |
| 90 days | -35.1% | -21% | 7.2% |
| 1 year | -30.1% | -21.9% | 12.2% |
DNLI vs Sector: Denali Therapeutics Inc. has significantly underperformed the "Healthcare" sector by -8.27% over the past year.
DNLI vs Market: Denali Therapeutics Inc. has significantly underperformed the market by -42.33% over the past year.
Stable price: DNLI is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: DNLI with weekly volatility of -0.5796% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (13.42 $) is lower than the fair price (17.99 $).
Price significantly below the fair price: The current price (13.42 $) is 34.1% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (62.94) is higher than that of the sector as a whole (53.14).
P/E vs Market: The company's P/E (62.94) is higher than that of the market as a whole (62.2).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.71) is lower than that of the sector as a whole (10.86).
P/BV vs Market: The company's P/BV (2.71) is lower than that of the market as a whole (20.84).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (9.13) is higher than that of the sector as a whole (4.06).
P/S vs Market: The company's P/S indicator (9.13) is lower than that of the market as a whole (16.02).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-7.72) is lower than that of the sector as a whole (16.98).
EV/Ebitda vs Market: The company's EV/Ebitda (-7.72) is lower than that of the market as a whole (27.16).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -138.92% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-138.92%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-10.32%).
5.4. ROE
ROE vs Sector: The company's ROE (-37.4%) is higher than that of the sector as a whole (-83.36%).
ROE vs Market: The company's ROE (-37.4%) is lower than that of the market as a whole (43.08%).
5.5. ROA
ROA vs Sector: The company's ROA (-33.45%) is lower than that of the sector as a whole (6.41%).
ROA vs Market: The company's ROA (-33.45%) is lower than that of the market as a whole (23.27%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.29%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.26%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
